OMA Stock Chart & Stats
€0.01
>-€0.01(-4.76%)
At close: 4:00 PM EST
€0.01
>-€0.01(-4.76%)
Day’s Range― - ―
52-Week Range€0.21 - €1.66
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€8.92M
Enterprise Value€70.59
Total Cash (Recent Filing)€23.51M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta2.93
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.79
Shares Outstanding11,071,369
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio8.38
Price to Book (P/B)58.31
Price to Sales (P/S)0.00
P/FCF Ratio-165.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.28
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageManageable leverage limits interest and refinancing pressure compared with a highly indebted structure. This provides some financial flexibility to continue oncology development, although the declining equity base reduces the protection this advantage provides.
Narrower Annual LossThe year-over-year reduction in net loss indicates some improvement in cost absorption or operating efficiency. It is not yet evidence of profitability, but sustained progress could extend the company’s development runway and improve funding prospects.
Focused Oncology PipelineA focused oncology strategy can support differentiated expertise and concentrated development resources rather than spreading investment across unrelated markets. Drug-delivery approaches may also create partnering or licensing opportunities if clinical value is demonstrated.
Bears Say
No Recent Reported RevenueThe absence of reported revenue shows that Vivesto currently lacks a demonstrated commercial operating base. Without product sales or recurring partnership income, future value remains dependent on successful development, approvals, and external financing.
Persistent Operating Cash BurnContinued operating cash outflows mean the business is not self-funding and must rely on cash reserves, equity, debt, or partnerships to advance its pipeline. Prolonged burn increases dilution and execution risk before products generate revenue.
Shrinking Capital CushionMaterial equity erosion reflects cumulative losses and leaves less capital to absorb further development setbacks. Negative returns on equity also show that shareholder funding is not currently producing profitable operations, weakening long-term financial resilience.
Vivesto AB News
OMA FAQ
What was Vivesto AB’s price range in the past 12 months?
Vivesto AB lowest stock price was €0.21 and its highest was €1.66 in the past 12 months.
What is Vivesto AB’s market cap?
Vivesto AB’s market cap is €8.92M.
When is Vivesto AB’s upcoming earnings report date?
Vivesto AB’s upcoming earnings report date is Nov 12, 2026 which is in 76 days.
How were Vivesto AB’s earnings last quarter?
Vivesto AB released its earnings results on Aug 13, 2026. The company reported -€0.069 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Vivesto AB overvalued?
According to Wall Street analysts Vivesto AB’s price is currently Overvalued.
Does Vivesto AB pay dividends?
Vivesto AB does not currently pay dividends.
What is Vivesto AB’s EPS estimate?
Vivesto AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vivesto AB have?
Vivesto AB has 11,071,369 shares outstanding.
What happened to Vivesto AB’s price movement after its last earnings report?
Vivesto AB reported an EPS of -€0.069 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.872%.
Which hedge fund is a major shareholder of Vivesto AB?
Currently, no hedge funds are holding shares in DE:OMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vivesto AB
Vivesto AB, established in 1988 and headquartered in Solna, Sweden, specializes in the development, production, commercialization, and sale of pharmaceutical products within human and veterinary oncology, primarily operating in its home country. Its leading human oncology product is Apealea (paclitaxel micellar), designed for the treatment of ovarian cancer. The company's pipeline for human health also includes Docetaxel micellar, a patented formulation combining the cytotoxin docetaxel with XR-17, which is currently in Phase 1b clinical trials for prostate cancer, as well as Cantrixil for addressing ovarian cancer. For animal health, Vivesto provides Paccal Vet, leveraging its XR-17 encapsulation technology to deliver paclitaxel for canine mastocytoma, and Doxophos Vet, a proprietary doxorubicin formulation used to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) until its name change to Vivesto AB in March 2022.
Technical Analysis
Clinical Laserthermia Systems AB Class B
―
SpectraCure AB
―
Nanologica AB
―
Spago Nanomedical AB
―
Nanexa AB
―